# Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries

**Authors:** Stuart Astbury, Edmond Atallah, Jane I Grove, Amber G Bozward, Scott P Davies, Mark J Sheehan, Steven W Kumpf, Jessie Qian, Natalia M Krajewska, Grace E Wootton, Melanie R Lingaya, Davor Kresnik, Flavia Radulescu, Ankit Rao, Hester Franks, Lourdes Ruiz-Ortega, Mar Riveiro-Barciela, Shashi K Ramaiah, Thomas A Lanz, Changhua Ji, Poulam M Patel, Ye H Oo, Guruprasad P Aithal

PMC · DOI: 10.1136/jitc-2025-014178 · Journal for Immunotherapy of Cancer · 2026-03-27

## TL;DR

This study identifies a specific type of CD8+ T cell that can help distinguish liver injury caused by cancer immunotherapy from other similar conditions.

## Contribution

The study discovers a unique CD8+ T-cell subset as a potential biomarker for checkpoint inhibitor-induced liver injury.

## Key findings

- CD8+ effector memory T cells with high CD38, HLA-DR, and CXCR3 expression correlate with liver injury severity.
- ChILI shows increased resident CD8+ T cells and CXCR-related gene activity compared to other liver injuries.
- Soluble CD27 and PD-1 are elevated in ChILI patients, offering potential diagnostic markers.

## Abstract

Checkpoint inhibitor-induced liver injury (ChILI) is an immune-related adverse reaction, occurring in patients with cancer receiving immune checkpoint inhibitors (CPI). ChILI is currently managed with high doses of corticosteroids which carry their own risks and potential side effects, and the lack of available biomarkers makes monitoring patients at risk of developing ChILI a challenge. There is no specific test that distinguishes ChILI from other competing diagnoses such as acute autoimmune hepatitis (AIH) and idiosyncratic drug-induced liver injury (DILI) due to other medications.

Patients with cancer taking immunotherapy who did and did not develop ChILI were recruited. Patients gave samples during the acute phase of liver injury, before CPI treatment and at 12 weeks following the start of CPI therapy if no toxicity developed. Healthy controls were recruited as well as patients with DILI and AIH. Whole blood was taken for broad immune phenotyping using mass cytometry, peripheral blood mononuclear cells were isolated for validatory flow cytometry and single-cell RNA sequencing (RNA-seq), and plasma was used for cytokine profiling. Samples from a second ChILI cohort were used for validation. Snap-frozen liver biopsies were used for bulk RNA-seq to compare the immune response in ChILI to DILI and AIH and correlate with peripheral immune signals. Formalin-fixed paraffin-embedded liver biopsies were used to visualize liver CD8+ T-cell infiltration using confocal microscopy.

We have identified a circulating CD8+ effector memory T-cell subset, expressing high levels of CD38, HLA-DR and CXCR3 and significantly correlated with alanine transaminase. Flow cytometry and single-cell RNA sequencing revealed an increase in granzyme expression, the liver residency marker CD69 and exhaustion markers CTLA-4, PDCD1 and HAVCR2 relative to other CD8+ effector subsets. Liver tissue bulk RNA-seq and immune cell deconvolution showed a significant increase in resident CD8+ T cells in ChILI compared with DILI and AIH, and a significant upregulation of genes related to CXCR chemokine receptor binding. Plasma cytokine profiling highlighted soluble CD27 and PD-1 as significantly elevated in ChILI relative to controls on CPI.

We have shown that circulating CD8+ T cells provide a potential biomarker to distinguish ChILI from DILI and AIH, and highlight different mechanistic pathways between ChILI and other immune-mediated liver injuries.

## Linked entities

- **Genes:** CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493], PDCD1 (programmed cell death 1) [NCBI Gene 5133], HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868], il8r (interleukin 8 receptor) [NCBI Gene 100135914]
- **Proteins:** CD38 (CD38 molecule), CXCR3 (C-X-C motif chemokine receptor 3), granzyme (granzyme K-like), CD69 (CD69 molecule), CD27 (CD27 molecule), PDCD1 (programmed cell death 1)

## Full-text entities

- **Genes:** CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, GZMK (granzyme K) [NCBI Gene 3003] {aka GrK, TRYP2}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, Cxcr3 (C-X-C motif chemokine receptor 3) [NCBI Gene 12766] {aka Cd183, Cmkar3}, CDK9 (cyclin dependent kinase 9) [NCBI Gene 1025] {aka C-2k, CDC2L4, CTK1, PITALRE, TAK}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, HOXD13 (homeobox D13) [NCBI Gene 3239] {aka BDE, BDSD, HOX4I, SPD, SPD1}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, Tlr9 (toll-like receptor 9) [NCBI Gene 81897], CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Ctla4 (cytotoxic T-lymphocyte-associated protein 4) [NCBI Gene 12477] {aka Cd152, Ctla-4, Ly-56}, CDK7 (cyclin dependent kinase 7) [NCBI Gene 1022] {aka CAK, CAK1, CDKN7, HCAK, MO15, STK1}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, Ccr2 (C-C motif chemokine receptor 2) [NCBI Gene 12772] {aka Cc-ckr-2, Ccr2a, Ccr2b, Ckr2, Ckr2a, Ckr2b}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 397286], CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, CCL27 (C-C motif chemokine ligand 27) [NCBI Gene 10850] {aka ALP, CTACK, CTAK, ESKINE, ILC, PESKY}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** non-alcoholic steatohepatitis (MESH:D005235), tuberculosis (MESH:D014376), infection (MESH:D007239), cytomegalovirus (MESH:D003586), CPI (MESH:D054179), toxicities (MESH:D064420), arthritis (MESH:D001168), hepatocellular carcinoma (MESH:D006528), fibrosis (MESH:D005355), Cancer (MESH:D009369), acute liver injury (MESH:D017114), acute autoimmune hepatitis (MESH:D020275), viral hepatitis (MESH:D014777), melanoma (MESH:D008545), ChILI (MESH:D056486), chronic hepatitis B virus (HBV) infection (MESH:D019694), autoimmune diseases (MESH:D001327), TB (MESH:D014390), AIH (MESH:D019693), inflammation (MESH:D007249), EBV (MESH:D020031), immune-mediated liver disease (MESH:D008107), cholestatic (MESH:D002779), renal cell carcinoma (MESH:D002292), -mediated liver injuries (MESH:D017093)
- **Chemicals:** ipilimumab (MESH:D000074324), Cenicriviroc (MESH:C506967), CPI (-), nivolumab (MESH:D000077594), bilirubin (MESH:D001663), Formalin (MESH:D005557), NAD+ (MESH:D009243), paraffin (MESH:D010232), amodiaquine (MESH:D000655), pembrolizumab (MESH:C582435), steroid (MESH:D013256)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13034233/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13034233/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC13034233/full.md

---
Source: https://tomesphere.com/paper/PMC13034233